Ab­b­Vie signs mR­NA pact with An­i­ma Biotech for $42M up­front

Ab­b­Vie is part­ner­ing on mR­NA, hop­ing to de­vel­op new med­i­cines with the help of a small biotech’s tech­nol­o­gy plat­form, the com­pa­ny an­nounced to­day.

An­i­ma Biotech will re­ceive an up­front pay­ment of $42 mil­lion from Ab­b­Vie. An­oth­er $540 mil­lion is on the line in the form of op­tion fees and re­search and de­vel­op­ment mile­stones for the dis­cov­ery and de­vel­op­ment of mR­NA bi­ol­o­gy mod­u­la­tors across three tar­gets in on­col­o­gy and im­munol­o­gy us­ing the com­pa­ny’s Light­ning plat­form. Com­mer­cial mile­stones and tiered roy­al­ties could al­so lead to more pay­outs for An­i­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER